Clinical Trial

Promising Phase 2 data for AP-101 shows it slows ALS progression by targeting a key toxic protein, offering new hope beyond purely genetic approaches.

A new RNA therapy for obesity is advancing in trials. It promises to reduce harmful visceral fat, preserve muscle, and may only require a twice-yearly dose.

A novel drug for glioblastoma enters a revolutionary trial, but the real story is the mission-driven company behind it, rewriting the rules of drug development.

Heparin, a trusted blood thinner, can trigger a fatal immune reaction. A small biotech's novel drug is now taking the global stage with a targeted solution.

A key FDA alignment for zervimesine not only de-risks a pivotal trial but signals a new era for treating the devastating psychosis of an overlooked dementia.

Early trial data for Verastem Oncology's VS-7375 reveals significant anti-tumor activity and a good safety profile, igniting hope for tough-to-treat cancers.

A medical breakthrough in neurostimulation could dramatically increase the supply of lungs for transplant, tackling a critical shortage and saving lives.

With a key grant from Breakthrough T1D, MannKind aims its inhaled insulin at children. Is this a life-changing innovation or a high-stakes corporate revival?

A novel drug aims to reverse myelin damage in MS, a feat no current therapy can achieve. But with a recent FDA hold, is Quantum BioPharma's vision a breakthrough or a mirage?

SRX Global's investment in ARMR Sciences' long-lasting fentanyl countermeasure signals a paradigm shift from reactive treatment to proactive biodefense.

Zevra Therapeutics' new data for MIPLYFFA in infants with NPC is more than a medical update; it's a key commercial milestone to widen its market.

With a promising drug, fresh cash, and a new board member known for billion-dollar exits, Avalo Therapeutics is signaling a major strategic shift.

Amylyx reveals positive initial safety data for its new ALS drug, AMX0114, a critical step as the firm aims to rebuild after the Relyvrio withdrawal.

Teleflex launches a pivotal trial for a magnesium stent that vanishes in a year. Can it erase the memory of past failures and redefine cardiovascular care?

A Boston biotech advances a first-in-class antibody into trials, aiming to halt the cellular engine of fibrosis that drives chronic kidney disease.

Skye Salud's move into primary care testing in Mexico is more than a trial; it's a blueprint for deploying resilient, evidence-based AI in regulated industries.

With a $43M funding boost, Irish innovator CroíValve is expanding trials for its unique 'Adaptive Coaptation' device, aiming to transform treatment for millions.

Elevar Therapeutics' new trial for lirafugratinib aims for a tumor-agnostic label, a strategic move to redefine cancer treatment beyond a single indication.

New 2- and 3-year data shows lebrikizumab sustains skin clearance with less frequent dosing, offering patients flexibility and positioning Eli Lilly for a major market share.

For bladder cancer patients facing bladder removal, a novel therapy from Sweden offers new hope. A US trial expansion targets the most resistant cases.